[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 2 sources · 18 days · First seen · Last updated

Oncobiologics financial performance and insider trading

Overview

Oncobiologics, Inc. has experienced significant insider trading activity alongside fluctuating financial performance. In late July, Director Faisal Ghiath Sukhtian purchased 95,398 shares at an average price of $1.05 per share.

By mid-August, Oncobiologics reported quarterly earnings that missed analyst expectations, posting earnings per share of ($0.09) against an estimated ($0.08) and revenue of $0.01 million against an estimated $0.97 million. Despite this miss, Director Sukhtian significantly increased his position on August 12th by purchasing 2,525,252 shares at an average cost of $0.99 per share, a transaction valued at approximately $2.5 million. Additionally, Goldman Sachs Group Inc. increased its position in the company by 74.1% during the first quarter.

Entities

SEC · Aktis Oncology · Ken Herrmann · Goldman Sachs Group Inc. · Faisal Ghiath Sukhtian

Timeline

  1. 7 days ago

    [BUSINESS] 2 sources
    Oncobiologics reports quarterly earnings miss and director stock purchase

    Oncobiologics (NASDAQ:OTLK) reported quarterly earnings of ($0.09) per share, missing estimates, while Director Ghiath Sukhtian purchased over 2.5 million shares.

  2. 24 days ago

    [BUSINESS] 2 sources
    Oncobiologics and Aktis Oncology Directors Trade Shares

    Oncobiologics director Faisal Ghiath Sukhtian bought 95,398 shares; Aktis Oncology director Ken Herrmann sold 4,856 shares, affecting their holdings.

Sources

mommygearest.com · stocknews.com